Considerations And Challenges Associated With Manufacturing Autologous Cellular Therapies Such As Car T Cells by Maier, Dawn
CONSIDERATIONS AND CHALLENGES ASSOCIATED WITH MANUFACTURING AUTOLOGOUS 
CELLULAR THERAPIES SUCH AS CAR T CELLS 
 




Key Words: CAR T cells, Manufacturing Challenges, Autologous Cell Therapies, Gene Therapy  
 
Adoptive Immunotherapy, the transfer of autologous T cells that have been genetically modified ex vivo and 
given back to the patient for the treatment of cancer and other immune-related disorders, is an exciting and 
emerging field that has grown significantly in the past five years. What was once considered a boutique therapy 
with minimal potential has demonstrated the potential to be an effective and durable treatment and has certainly 
gotten the attention of multiple drug development companies. Although this is good news, as these therapies 
are finally getting the attention they deserve, it is important to understand the complexity and challenges 
associated with developing and scaling up such therapies. Unlike traditional drug development, where the 
starting material is the same every time, with autologous cellular therapies, the starting material for 
manufacturing the drug is different for each patient. Therefore understanding patient-to-patient variability is 
critical. In addition, for such therapies to be successful, it is important to shift the paradigm of traditional drug 
development, and for scientists, clinical investigators, regulatory agencies and payers alike to come together to 
think of novel ways to bring these potentially life-changing therapies to market. Due to the nature and complexity 
of the manufacturing process, it is important that activities such as process characterization are considered 
earlier in the development process. Some key challenges, aside from patient-to-patient variability, that are 
associated with developing autologous cellular therapies include availability of patient material for development, 
availability of qualified assays, cost of goods, technical expertise, manufacturing and disposition times, and 
establishing  appropriate scale-down models.    
 
